In recent years, immunotherapy has been shown to be a promising approach for the treatment of various tumor entities. Due to further pharmacological developments and new studies, the checkpoint inhibitors have now arrived in the clinic. To date, patients with cancers in the head and neck region have benefited from these agents as part of a palliative therapy. Current clinical trials are testing other indications for the checkpoint inhibitors as monotherapy or in combination with other therapeutic approaches. The following article summarizes the highlights of the American Society of Clinical Oncology (ASCO) Annual Meeting.
|Translated title of the contribution||Immuno-, radio-, and chemotherapeutic studies in head and neck cancer: Highlights of the ASCO Annual Meeting 2017|
|Number of pages||7|
|Publication status||Published - 01.03.2018|